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ABSTRACT 
Objective: Development of a stability-indicating reverse phase liquid chromatographic (RP-HPLC) method for the simultaneous quantification of 11 
impurities in the combined dosage forms of lamivudine and tenofovir disoproxil fumarate drug substances. 
Methods: Efficient chromatographic separation of all analytes was achieved on a Waters X-terra RP18 column (150 x 4.6 mm, 3.5 µm) using mobile 
phase A (ammonium acetate buffer, pH adjusted to 5.0±0.05 with dilute orthophosphoric acid) and mobile phase B (mixture of methanol and 
ammonium acetate buffer in the ratio of 20:80) with the flow rate of 1.0 ml/min in gradient elution mode at 260 nm.  
Results: The method was validated in terms of the limit of detection, limit of quantification, linearity, accuracy, precision and robustness according 
to the international conference on harmonisation (ICH Q2R1). Regression analysis showed that the correlation coefficient (r2) is greater than 0.997 
for individual active drug substances as well as their related substances. The method has proven very accurate (94.6 % to 108.2 % with % RSD not 
more than 4.9), highly precise (% RSD of the Intra-day and the inter-day study was not more than 8.9) and robust enough to deliver accurate results, 
when the chromatographic conditions were altered intentionally. Forced degradation studies were conducted in acidic, basic, thermal, photolytic, 
humid and peroxide stress conditions, where all the degradation peaks were monitored. Highest degradation of lamivudine was observed under 
oxidative stress condition and tenofovir was more susceptible to degradation under acidic and alkaline conditions.  
Conclusion: The present method is able to separate all the related compounds with each other and with the main drug substances with the 
resolution more than 2.0. The test solution was found to be stable in diluent up to 24 h. The mass balance of forced degradation of formulations, 
close to 99 %, made this method as a stability indicating method.  
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Tenofovir disoproxil fumarate {9-[(R)-2-[[bis [[isopropoxycarbonyl] 
oxy] methoxy] phosphonyl] methoxy] popyl] adenine fumarate} is a 
nucleotide analog reverse transcriptase inhibitor (NRTI) and is used 
for treating HIV infection in adults in combination with other 
antiretroviral agents. Lamivudine {4-amino-1-[(2R, 5S)-2-(hydroxyl 
methyl)-1,3-oxathiolan-5-yl]-1,2-dihydro pyrimidin-2-one} is an 
another NRTI used in the treatment of HIV infection and chronic 
hepatitis B virus (HBV) [1-2]. The combination of these two drugs is 
available in the market with brand names of Forstavir 30s tablet, 
Tavin 30s tablet, Ricovir 30s tablet, Tenolam 30s tablet, Envir 30s 
tablet with 300 mg strength of each rugs substance. Total eleven 
specified impurities are present in both lamivudine and tenofovir out 
of which, four impurities are related to lamivudine and seven 
impurities (including one dimer) are related to tenofovir. As per the 
ICH guidelines, all these related substances must be controlled below 
0.2 % of the drug concentration except monoester and isopropyl 
ethers and limits should not exceed 0.2 % at various storage 
conditions.  
As per the USP monograph, the specification limits for tenofovir 
monoester and tenofovir isopropyl impurities are 1.0 % and 0.3 %, 
respectively. Under various environmental conditions, a change in the 
purity of these drug substances is common and it results in change in the 
amount of impurities. In order to maintain the quality of these drug 
substances, degradation study of combined dosage forms is of prime 
importance for the determination of the various degraded impurities. 
 
 
Fig. 1: Chemical structures of lamivudine, tenofovir and its impurities 
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The literature review revealed that most efforts were put in 
developing analytical methods for estimating the lamivudine and 
tenofovir drug substances, either individually or in combination 
with other drugs in different dosage forms or biosamples which 
includes spectrophotometric method [3-6], high performance liquid 
chromatography [7-18], ultra-performance liquid chromatography 
[19, 20] and mass spectrometry [21-23]. Rao et al. [18], reported a 
stability indicating a method for the simultaneous estimation of 
lamivudine, tenofovir and dolutegravir in bulk and their dosage 
forms. But, no any analytical method was reported for the 
simultaneous estimation of related substances in a combined dosage 
form of lamivudine and tenofovir. Therefore, the present study is 
aimed to develop a stability indicating high performance liquid 
chromatographic method for the determination of 11 impurities 
including two drug substances in the dosage forms. The structures of 
both the drug substances and related substances are presented in 
fig. 1 and chemical names are given in table 1. The method was 
validated as per the guidelines are given by food and drug 
administration (FDA) and international conference on 
harmonization (ICH) with respect to the limit of detection, limit of 
quantification, linearity, precision, accuracy, specificity and stability 
studies.
 
Table 1: Chemical names of lamivudine, tenofovir disoproxil fumarate and their impurities 
S. 
No. 
Name of the 
compounds 
IUPAC name 
1 Lamivudine 4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one 
2 Impurity-A (2RS,5SR)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolane-2-carboxylic acid 
3 Impurity-E 4-aminopyrimidin-2(1H)-one  
4 Impurity-F pyrimidine-2,4(1H,3H)-dione 
5 Impurity-H 4-Amino-1-[(2R,3R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl] pyrimidin-2(1H)-one S-oxide 
6 Tenofovir disoproxil 
fumerate  
Bis{[(isopropoxycarbonyl)oxy]methyl} ({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)phosphonate. 
7 Adenine impurity 6-Amino purine 
8 Mono ester impurity [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid monoisopropoxycarbonyloxymethyl ester. 
9 Ethyl impurity Isopropyloxycarbonyloxy methy (ethoxy)-(R)-9-[2 phosphono methoxy) propyl adinine 
10 Isopropyl impurity Isopropyl ether (R)-9-(2-mono isopropoxy carbonyl oxy methyl phosphine methyl) propyladenine 
11 n-propyl impurity [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid isopropoxycarbonyloxymethyl ester-
methoxycarbonyloxymethyl ester, fumarate. 
12 Tenofovir impurity (R)-1-(6-Amino-9H-purine-9-yl) propane-2-yloxy)methyl phosphonic acid 
13 Dimer impurity [2-[6-[[[9-(Bis-isopropoxycarbonyloxy methoxy phosphonyl-methoxy)propyl]-9Hpurin-6-ylamino]methyl]amino]-
purin-9-yl]-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxy methyl ester. 
 
MATERIALS AND METHODS 
Chemicals and reagents 
Reference standards of drug substances and related compounds are 
supplied by GSN Pharmaceuticals private limited, Hyderabad as gift 
samples. Lamivudine and tenofovir tablet dosage forms were 
purchased from local market. HPLC grade acetonitrile was procured 
from Qualigens, India. Ammonium acetate and orthophosphoric acid 
were purchased from Merck, India. All other chemicals and solvents 
of analytical grade were supplied by Merck, India. Water used in the 
HPLC analysis was purified by the water purifier (Milli-Q Millipore). 
The mobile phase and all the solutions were filtered through a 0.45 
mm nylon filter (Millipore). 
Instrumentation 
The HPLC system was composed of 2695 waters alliance system fixed 
with 2996 PDA detector with Empower 2 software. Analytical column 
used for this method is Waters x-terra RP18 (150 mm x 4.6 mm, 3.5 µm). 
Operating conditions of HPLC 
Initially, several trial runs were carried out to select suitable a 
solvent system for accurate and precise analysis and to achieve a 
proper resolution of analytes. Various parameters like columns, 
solvent type, solvent and buffer ratio, the flow rate of the mobile 
phase and wavelength were tried to establish the chromatographic 
conditions for the separation of related compounds in short run 
time. Finally, optimum parameters were found on X-terra RP18 (150 
x 4.6 mm, 3.5 µm) column and the mixture of mobile phase A 
consisting of mixed ammonium acetate (pH adjusted to 5.0±0.05 
with dilute OPA) and mobile phase B consisting of a mixture of 
methanol and above ammonium acetate buffer in the ratio of 20:80 
(v/v) at a flow rate of 1 ml/min in gradient elution mode with 
column temperature at 35 °C. Gradient time program as set as a time 
in minutes/% of mobile phase B composition 0/0, 45/90, 53/90, 
54/0, 60/0. Before delivering the mobile phase into the system, it 
was degassed and filtered through 0.45 µm nylon filter using the 
vacuum. The injection volume was 10 µl and the detection was 
performed at 260 nm using a photodiode array (PDA) detector. The 
typical retention times of lamivudine and tenofovir are 7.85 min and 
30.11 min respectively. The criticality of this method is to elute the 
entire active compounds as well as their related impurities with 
optimum separation and symmetric peak shapes in short run time.  
Preparation of mobile phases 
Mobile phase A prepared by taking 1.53 g of ammonium acetate into 
a beaker containing 1000 ml of water (0.02 N) and adjusted the pH 
of the resultant solution to 5.0±0.05 with diluted orthophosphoric 
acid and filtered through a 0.45 µm filter. Mobile phase B prepared 
by mixing of methanol and ammonium acetate buffer in the ratio of 
20:80 (v/v). Diluent is prepared mixing of methanol and ammonium 
acetate buffer in the ratio of 80:20 (v/v). 
Stock and standard solution preparation 
Stock solution (100 µg/ml) was prepared by dissolving about 10 mg 
of each lamivudine and tenofovir into 100 ml volumetric flask, added 
75 ml of diluent and sonicated to dissolve and diluted to volume 
with diluent and mixed well. Standard solution (1 µg/ml) was 
prepared by transferring 1.0 ml of the above stock solution into a 
100 ml volumetric flask and diluted with diluent up to the mark. 
Sample preparation 
10 tablets were separately weighed and ground into fine powder by 
using mortar and pestle. An amount equivalent to 100 mg of 
lamivudine and tenofovir was transferred into a 200 ml volumetric 
flask, added 150 ml of diluent and sonicated to extract all the active 
compounds and their related impurities completely and made up to 
the volume with diluent and mixed well. A portion of the above 
solution was filtered through 0.45 µm nylon syringe filter and 
discarded first 2 ml of the filtrate followed by collecting the 
remaining filtrate into the 2 ml HPLC vial. 
RESULTS AND DISCUSSION 
Separation of lamivudine, tenofovir and related substances was 
achieved with the above optimized conditions and the method was 
validated as per ICH Q2 (R1) guideline and current industrial 
practices.  
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The aim of method validation is to confirm that the present method 
is suitable for its intended use purpose. The described method has 
been extensively validated in terms of specificity, limit of detection 
(LOD) and quantification (LOQ), linearity, accuracy, precision, 
robustness and solution stability. The precision was expressed in 
terms of intraday and interday variation in the expected drug 
concentrations. The accuracy was expressed in terms of percent 
recovery by adding a known amount of impurities to the sample 
preparation. 
System suitability  
The system suitability was evaluated by a series of six injections of 
the standard solution with the concentration of 1 µg/ml. The system 
suitability criteria like % RSD, USP tailing factor and USP theoretical 
plates summarized in table 2. The corresponding standard 
chromatogram is shown in fig. 2. As per the results tabulated in table 
2 system suitability parameters are fixed as % RSD of all the 
injections should be less than 5 and tailing factor should not more 
than 2.0 and the limit for theoretical plates should more than 5000 
for both the peaks. 
  
Table 2: System suitability results 

















1 7.85 27222 1.18 12579 30.11 37119 1.18 13213 
2 7.84 27121 1.17 12614 30.10 37108 1.18 13196 
3 7.87 27037 1.18 12678 30.08 37155 1.18 13233 
4 7.82 27069 1.18 12689 30.14 37160 1.17 13254 
5 7.80 27175 1.18 12632 30.18 37110 1.18 13252 
6 7.81 27268 1.17 12589 30.12 37083 1.18 13264 
Mean  27149    37120   
SD  89.323    30.773   
%RSD  0.33    0.08   
 
 
Fig. 2: Typical chromatogram of standard solution 
 
Table 3: Specificity results of spiked sample 
S. No  Name RT RRT Purity angle Purity threshold Peak purify 
1 Fumaric acid  1.62 0.21 12.501 14.254 Pass 
2 Impurity-E 2.12 0.27 10.124 15.587 Pass 
3 Impurity-F 2.49 0.32 0.584 2.157 Pass 
4 Impurity-A 2.78 0.36 5.687 6.789 Pass 
5 Impurity-H 3.63 0.46 1.242 3.610 Pass 
6 Adenine  5.96 0.76 3.547 4.587 Pass 
7 Tenofovir impurity  6.35 0.81 9.125 13.524 Pass 
8 Lamivudine  7.81 1.00 14.254 16.245 Pass 
9 Mono ester impurity  19.36 2.48 0.554 1.021 Pass 
10 Di ehyl impurity  25.39 3.25 3.014 3.541 Pass 
11 Isopropyl impurity  27.37 3.50 6.647 6.847 Pass 
12 Tenofovir disoproxil 30.11 3.85 1.201 1.542 Pass 
13 n-Propyl impurity  30.66 3.93 3.125 4.852 Pass 
14 Tenofovir dimer impurity  44.17 5.65 2.325 2.854 Pass 
RT= Retention time, RRT= Relative retention time 
 
Specificity 
The specificity of the present method was checked by injecting 
blank, placebo preparations and samples by spiking with 
appropriate levels of impurities and demonstrated the separation of 
these impurities individually and/or from other components in the 
sample matrix of tenofovir, lamivudine. The chromatograms of the 
blank and spiked sample for the specificity study are included in fig. 
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3 and fig. 4. The results of the specificity in terms of retention time 
(RT) and relative retention time (RRT), purity angle, purity threshold 
and peak purity of all analytes are included table 3. The 
chromatograms of blank and placebo in fig. 3 and fig. 4 showed that no 
any peak was found at the retention times of impurities. The spiked 
chromatogram presented in fig. 5 showed that all the peaks are well 
separated with each other with resolution more than 2.0 confirmed 
the specificity of the present method is good. The results presented in 
table 3 indicate that there is no interference between the peaks of 
impurities with main drug substances and the specificity of the 
method is confirmed by their peak purities i. e purity angle is less than 
purity threshold. Hence, the chromatographic system used for the 
estimation of related substances in tenofovir and lamivudine is very 
selective and specific. Rao et al. [18], presented a stability indicating a 
method for three drug combination formulations without impurity 
profile study. But, the present method is able to quantify all the 
individual impurities that arise during storage of both active 
pharmaceutical ingredient and tablet dosage forms. 
 
 
Fig. 3: Chromatogram of blank solution 
 
 
Fig. 4: Typical chromatogram of impurity spiked sample 
 
Forced degradation studies  
Intentional degradation was attempted at various stress conditions 
like the thermal sample (at 60 °C for 7 d), photolytic sample (1.2 
million lux h), humidity (at 90 % related humidity for 7 d), acid 
hydrolysis (using 0.5 N hydrochloric acid, 1h at room temperature), 
base hydrolysis (using 0.5 N sodium hydroxide, 1h at room 
temperature) and oxidative degradation (using 10 % hydrogen 
peroxide, 1h at room temperature) to evaluate the ability of the 
proposed method to separate degradation products from each other 
and active ingredients as well and to provide an indication of 
stability indicating property of the method. To check and ensure the 
homogeneity (peak purity) of all peaks in the stressed sample 
solutions, photodiode array detector was employed. The results of 
forced degradation study presented in table 4 indicate that tenofovir 
is susceptible for degradation in acid, base and high humidity stress 
conditions, whereas lamivudine is susceptible to peroxide and high 
humidity stress conditions. 
Limit of detection and quantification 
Limit of detection (LOD) and limit of quantification (LOQ) for related 
substances are determined by injecting a series of solutions of 
known concentration till the signal-to-noise ratio became as 3:1 and 
10:1, respectively, and the corresponding values are summarized in 
table 5. The found LOQ values are sufficient to quantify these 
impurities below the 0.2 % of the drug concentration as per the 
limits defined by pharma regulating agencies. The LOD and LOQ 
values are determined as 0.048 µg/ml and 0.160 µg/ml for 
lamivudine and 0.035 µg/ml and 0.115 µg/ml for tenofovir 
respectively, which are lower values when compared to earlier 
methods [18]. 
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Table 4: Forced degradation results 
Sample details Lamivudine Tenofovir disoproxil Peak purity of both 












As such sample 0.23 100.6 - 0.85 100.1 - Pass 
Thermal sample  0.25 100.4 99.8 0.91 98.2 99.0 Pass 
Photolytic sample  0.17 100.5 100.1 1.12 97.8 98.8 Pass 
Humidity sample 2.5 97.2 99.1 0.51 98.1 98.5 Pass 
Acid degradation  2.18 97.7 99.5 8.5 91.9 100.3 Pass 
Base degradation  1.5 98.3 99.4 11.5 89.8 101.2 Pass 
Oxidative 
degradation  
14.2 84.9 98.8 1.5 99.2 100.6 Pass 
 
Table 5: LOD and LOQ concentration of analytes along with S/N ratios 
S. No  Name LOQ conc. (µg/ml) s/n ratio LOD conc. (µg/ml) s/n ratio 
1  Impurity-E  0.095 10.3 0.029 3.1 
2  Impurity-F  0.110 11.5 0.033 3.8 
3  Impurity-A  0.045 10.6 0.014 3.0 
4  Impurity-H  0.105 9.8 0.032 2.7 
5  Adenine  0.140 12.2 0.042 3.8 
6  Tenofovir impurity  0.060 10.4 0.018 3.2 
7  Lamivudine  0.160 11.1 0.048 3.6 
8  Mono ester impurity  0.085 10.3 0.026 3.1 
9  Di ethyl impurity  0.105 11.5 0.032 3.8 
10  Isopropyl impurity  0.065 10.6 0.020 3.0 
11  Tenofovir disoproxil 0.115 9.8 0.035 2.7 
12  n-propyl impurity  0.170 12.2 0.052 3.0 
13  Tenofovir dimer impurity  0.045 10.4 0.014 3.2 
n=1, LOD = Limit of detection and LOQ = Limit of quantification and Linearity, range and relative response factor  
 
A series of solutions of lamivudine, tenofovir and all impurities 
solutions with concentrations ranging from LOQ to 150 % of 
specification level (impurities specification not more than 0.2 %) 
were prepared and injected into the HPLC system. The linearity of 
the method was established by plotting a graph between the 
concentration and response of lamivudine, tenofovir and all 
impurities. The results of the linearity study are presented in table 6. 
The results in table 6 indicate that the detector response was found 
to be linear from LOQ to 150 % of specification level and squared 
correlation coefficient (r2) is more than 0.990 confirms the linearity 
the method. The relative retention factor (RRF) is critical for 
quantification of impurities. Establishment of the RRF is required to 
avoid the stability issues with impurity standards, to reduce the cost 
on the preparation of impurity standards, to reduce maintenance of 
impurity standards due to the lack of donation of impurity standards 
and difficulty in the synthesis and isolation of impurity standards. 
RRF is used to correct the difference in detector response of 
impurities with analyte peak. RRF is established by the linearity 
slope method with a linear range of solutions and corresponding 
RRF values of this method is summarized in table 6. 
 
Table 6: Linearity and RRF values of lamivudine, tenofovir and all impurities 
S. No  Name Correlation coefficient Y-intercept at 100% level RRF 
1  Impurity-E  0.999 -1.2 1.02 
2  Impurity-F  0.992 0.8 1.12 
3  Impurity-A  0.995 -2.5 0.98 
4  Impurity-H  0.991 1.8 1.15 
5  Adenine  0.999 -2.1 1.31 
6  Tenofovir impurity  0.998 1.8 1.21 
7  Lamivudine  0.995 3.1 1.00 
8  Mono ester impurity  0.996 -1.8 1.12 
9  Di ethyl impurity  0.995 2.5 0.95 
10  Isopropyl impurity  0.993 1.3 0.92 
11  Tenofovir disoproxil 0.999 3.6 1.00 
12  n-propyl impurity  0.994 -3.8 1.16 
13  Tenofovir dimer impurity  0.996 -4.1 1.01 
n=1, RRF = Relative retention factor 
 
Accuracy 
The accuracy of an analytical method is an expression of the 
agreement between the value which is accepted either as a 
conventional true value or an accepted reference value and the value 
found. The accuracy of the method is established in terms of 
recovery. Sample solutions for accuracy study were prepared in 
triplicate by spiking all impurities at the specification level (Not 
more than 0.2 % of each impurity) to the test sample at LOQ, 50 %, 
100 % and 150 % of the specification level and injected into the 
HPLC system. Individual % recovery, mean % recovery and % RSD 
at each level are presented in table 7. The recovery of samples was 
found to be within the range of 90 % to 110 % and agreement with 
the ICH guidelines. 
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Table 7: Accuracy results of lamivudine, tenofovir and all impurities 
S. No Name % recovery of triplicate samples  % mean of all 
levels±SD 
% RSD of all levels 
LOQ level 50% level 100% level 150% level 
1  Impurity-E  98.5 102.6 100.8 96.2 99.5±2.8 2.8 
2  Impurity-F  105.6 99.8 103.6 101.2 102.6±2.6 2.5 
3  Impurity-A  108.2 103.2 101.9 100.9 103.6±3.2 3.1 
4  Impurity-H  104.6 99.6 107.5 105.1 104.2±3.3 3.2 
5  Adenine  108.2 105.3 104.9 100.5 104.7±3.2 3.0 
6  Tenofovir impurity  95.6 100.6 100.9 106.4 100.9±4.4 4.4 
7  Lamivudine  99.3 102.1 103.1 103.1 101.9±1.8 1.8 
8  Mono ester impurity  103.5 101.6 102.3 104.9 103.1±1.4 1.4 
9  Di ethyl impurity  106.8 99.1 106.1 100.2 103.1±4.0 3.8 
10  Isopropyl impurity  108.3 103.8 97.2 103.5 103.2±4.6 4.4 
11  Tenofovir disoproxil 96.1 105.1 99.2 102.3 100.7±3.9 3.9 
12  n-propyl impurity  94.6 101.5 103.9 106.2 101.6±5.0 4.9 
13  Tenofovir dimer impurity  102.6 105.2 101.1 100.3 102.3±2.2 2.1 
n=3 at each level, SD = Standard deviation and % RSD = % Relative standard deviation 
 
Method precision and intermediate precision 
To evaluate the method precision for related substances, six 
replicates test preparations (n=6) of lamivudine and tenofovir 
tablets were prepared and spiked all individual known 
impurities at the specification level (0.2 % of drug substance) 
and analyzed as per method. The % of individual known 
impurities and % of total impurities were calculated and 
reported in table 8. The % RSD values were found to be below 
8.9 for all impurities and found to be more precise as per the ICH 
guidelines. The intermediate precision of the method was 
evaluated by adopting the same method by using a different 
HPLC system, the different column of the same make at different 
days and the results are tabulated in table 9. The % RSD values 
were found to be below 7.9 for all impurities and found to be 
method is more ruggedness. 
 
Table 8: Method precision results 
S. No. Name  Impurity (µg/ml) % mean 
±SD 
% RSD  
Spl-1 Spl-2 Spl-3 Spl-4 Spl-5 Spl-6 
1  Impurity-E  1.05 1.00 0.90 1.10 0.95 1.05 1.01±0.07 7.3 
2  Impurity-F  0.95 1.10 0.95 0.90 1.00 1.10 1.00±0.08 8.4 
3  Impurity-A  1.05 0.95 1.00 1.05 0.95 1.00 1.00±0.04 4.5 
4  Impurity-H  1.10 1.00 1.05 0.95 1.05 1.00 1.03±0.05 5.1 
5  Adenine  1.05 1.00 1.10 1.10 1.00 1.05 1.05±0.04 4.3 
6  Tenofovir impurity  1.00 0.95 1.00 0.95 0.90 0.95 0.96±0.04 3.9 
7 Monoester impurity 5.10 5.50 5.25 5.30 4.95 5.40 5.25±0.20 3.8 
8  Di ethyl impurity  1.05 1.00 0.90 1.00 0.95 1.05 0.99±0.06 5.9 
9  Isopropyl impurity  1.60 1.50 1.55 1.45 1.40 1.65 1.53±0.09 6.1 
10  n-Propyl impurity  1.10 1.05 1.00 1.05 1.00 0.95 1.03±0.05 5.1 
11 Tenofovir dimer impurity 1.05 0.95 1.00 0.95 0.90 1.15 1.00±0.09 8.9 
12 Total impurities 16.10 16.00 15.70 15.80 15.05 16.35 15.83±0.45 2.8 
 
Table 9: Intermediate precision results 
S. No. Name Impurity (µg/ml) % mean 
±SD 
% RSD  
Spl-1 Spl-2 Spl-3 Spl-4 Spl-5 Spl-6 
1 Impurity-E 1.10 0.90 1.10 1.05 1.00 1.05 1.03±0.08 7.1 
2 Impurity-F 1.05 0.95 1.00 1.10 0.95 1.10 1.03±0.07 7.3 
3 Impurity-A 1.05 1.00 1.10 0.95 0.90 1.00 1.00±0.07 5.6 
4 Impurity-H 0.95 1.10 0.95 1.00 1.10 1.05 1.03±0.07 5.7 
5 Adenine 1.00 1.15 0.95 1.10 0.95 1.10 1.04±0.09 6.3 
6 Tenofovir impurity 1.05 1.10 1.00 1.05 0.90 1.15 1.04±0.09 7.7 
7 Mono ester impurity 5.50 5.40 5.60 5.25 5.50 6.05 5.55±0.27 5.1 
8 Di ethyl impurity 0.90 1.00 1.05 0.90 0.95 1.00 0.97±0.06 5.9 
9 Isopropyl impurity 1.65 1.55 1.60 1.55 1.50 1.60 1.58±0.05 5.0 
10 n-Propyl impurity 1.05 1.05 0.95 1.00 1.15 1.05 1.04±0.07 5.6 
11 Tenofovir dimer impurity 1.05 1.15 1.05 1.00 1.10 0.95 1.05±0.07 7.9 
12 Total impurities 16.35 16.35 16.35 15.95 16.00 17.10 16.35±0.41 2.5 
Spl = Sample 
 
Robustness  
The robustness of the method was studied by injecting the blank and 
standards with deliberate changes in flow rate of the mobile phase 
(±0.1 ml/min), column temperature (±5 °C) and pH of the mobile 
phase buffer (±0.2). The results of the robustness are presented in 
table 10. Results tabulated in table 10 showed that method is not 
affected by intentional changes in the method parameters which was 
proved by tailing factors of standards are less than 2 and % RSD of 
six replicate standards is less than 2. 
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Table 10: Robustness results 
S. No. Robustness parameter Lamivudine Tenofovir 
% RSD Tailing factor Theoretical plates % RSD Tailing factor Theoretical plates 
1 Low flow (0.9 ml/min) 1.2 1.0 12451 0.8 1.1 13512 
2 High flow (1.1 ml/min) 1.0 1.1 10147 1.1 1.0 13602 
3 Low buffer pH (4.8) 0.8 1.0 11458 0.2 1.1 12915 
4 High buffer pH (5.2) 0.4 1.2 10987 0.1 1.0 13025 
5 Low column temp. (30 °C) 1.1 1.0 12142 1.5 1.0 12854 
6 High column temp. (40 °C) 0.5 1.1 11411 1.2 1.1 12965 
n = 1 
 
Stability of analytical solutions 
To evaluate the stability, standard solution and the spiked sample 
solution were prepared and kept on the bench top (25 °C) and 
refrigerator (2-8 °C) conditions for 24 h. Similarity factor was 
calculated for a standard solution with a freshly prepared standard 
solution and the % of the difference of individual impurities and 
total impurities were calculated with the initial results. It was 
concluded that the standard solution is stable up to 24 h in bench 
top and refrigerator conditions. Sample solutions were unstable at 
bench top and refrigerator. Hence, samples were prepared freshly 
and injected immediately. 
CONCLUSION 
A specific, linear, precise and more accurate stability indicating high 
performance liquid chromatographic method has been developed 
for the quantification of 11 related substances including the 
tenofovir dimer impurity. The method has been validated for 
specificity, linearity, accuracy, precision, robustness and stability. 
This method is able to quantify all the impurities in the presence of 
other impurities and the main drug with less than 0.03 % of the drug 
concentration which is far times less than the specification level 
concentration (0.2 %). The method is linear in the range of LOQ to 
150 % of the specification concentration for all the impurities with a 
correlation coefficient not less than 0.99. The accuracy of the 
method is in the range of 94.6 % to 108.3 % for all impurities. As the 
method is validated according to the International council of 
harmonization (ICH) guidelines, it could be adopted for the analysis 
of all the related substances in the dosage forms of lamivudine and 
tenofovir in quality control labs, pharmaceutical industries and 
research laboratories.  
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